Clinical Studies & Research
Pharmaceutical trials for Alzheimer’s have failed repeatedly, but a new study using a fundamentally different approach based upon the science of Dale Bredesen, M.D., has provided the first clinical trial success: using precision medicine to identify and target the drivers of Alzheimer’s or pre-Alzheimer’s in each patient.
Alzheimer’s dementia is a complex neurodegenerative process and hundreds of possible contributing causes have been proposed and studied. The likelihood is high that there are multiple factors, some common to many cognitive patients and some more unique. When we identify and correct all of the common factors and also their unique issues, that is precision medicine!
Alzheimer’s disease is now the third leading cause of death in the United States [1-6], and the development of effective treatment and prevention is a major healthcare goal. However, clinical trials of drug candidates for Alzheimer’s disease treatment have been almost uniformly unsuccessful. There may be several reasons for such repeated failure: (1) given the long pre-symptomatic period, treatment is typically initiated late in the pathophysiological process; (2) what is referred to as Alzheimer’s disease is not a single disease, but rather exhibits several different subtypes...